Skip to content
Assyro AI
FDA Orange Book · active-ingredient family

Allopurinol sodium

Allopurinol sodium: 1 brand, 2 generics; first approved May 17, 1996; generic available.

Generic available
Generic status & protection

Generic available: 2 ANDA applications approved.

Brands (NDA)
1
Generics (ANDA)
2
Listed patents
0
Presentations
3

Brand (NDA) products

Originator applications
  • ALOPRIMRLDRS
    NDA 0202981996
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    EQ 500MG BASE/VIALINJECTABLEINJECTIONRxAP

Generic (ANDA) products (2)

Abbreviated applications
  • ALLOPURINOL SODIUM
    ANDA 2123632022
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    EQ 500MG BASE/VIALINJECTABLEINJECTIONRxAP
  • ALLOPURINOL SODIUM
    ANDA 0768702004
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    EQ 500MG BASE/VIALINJECTABLEINJECTIONRxAP

Listed patents

Orange Book patent file

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Approval history

FDA approval span
First approval
30 yr 8 mo ago
Most recent approval
4 yr 7 mo ago

Approvals span 1996–2022 across 3 FDA applications.

Brand (NDA) 133%
Generic (ANDA) 267%

Allopurinol sodium: frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.